Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials

摘要

Background The objective of this analysis was to assess the effects of edoxaban compared with enoxaparin on key coagulation biomarkers and present pooled primary efficacy and safety results from phase 3 STARS E-3 and STARS J-V trials for prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA) or total hip arthroplasty (THA). Methods In the randomized, double-blind, double-dummy, multicenter, STARS E-3 and STARS J-V trials, patients received edoxaban 30?mg or enoxaparin 2000?IU (20?mg) twice daily for 11 to 14?days. The studies were conducted in Japan and Taiwan; enoxaparin dosing was based on Japanese label recommendations. The primary efficacy endpoint was incidence of VTE; the safety endpoint was major or clinically relevant nonmajor (CRNM) bleeding. Blood samples were taken at presurgical evaluation, pretreatment (postsurgery), predose on day 7, predose on completion of treatment, and at a follow-up examination 25 to 35?days after the last dose of study drug for D-dimer, prothrombin fragment 1?+?2 (F₁₊₂), and soluble fibrin monomer complex (SFMC) measurement. Results A total of 716 patients enrolled in STARS E-3 and 610 patients enrolled in STARS J-V; 1326 patients overall. This analysis included 657 patients who received edoxaban 30?mg QD and 650 patients who received enoxaparin 20?mg BID. Incidence of VTE was 5.1 and 10.7% for edoxaban and enoxaparin, respectively ( P 1+2 (363 vs 463 pmol/L), and SFMC (5.7 vs 6.8?μg/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients, respectively ( P 1+2 (292 vs 380 pmol/L), and SFMC (6.2 vs 7.2?μg/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients ( P Conclusions Edoxaban was superior to enoxaparin in prevention of VTE following TKA and THA, with comparable rates of bleeding events. Relative to enoxaparin, edoxaban significantly reduced D-dimer, F₁₊₂, and SFMC. Trial registration Clintrials.gov NCT01181102 and NCT01181167 . Both registered 8/12/2010.